PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Phase III study compared neoadjuvant therapy with lapatinib or trastuzumab for early breast cancer

2010-12-11
(Press-News.org) SAN ANTONIO — Researchers presented Phase III efficacy data from the GeparQuinto study, a head-to-head comparison of neoadjuvant lapatinib and trastuzumab in combination with chemotherapy for patients with early breast cancer, at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12.

"We had a primary goal to compare the standard anti-HER2 neoadjuvant combination of chemotherapy, trastuzumab, with the new combination of chemotherapy and lapatinib," said Michael Untch, M.D., head of the multidisciplinary breast cancer department at Helios Clinic in Berlin, Germany.

The GeparQuinto study was conducted at 85 centers throughout Germany and includes 2,500 patients, 550 of whom have HER2-neu-overexpressing breast cancer. This is the largest prospective patient cohort of chemo-targeted neoadjuvant therapy worldwide.

All patients received four cycles of 90 mg/m2 epirubicin and 600 mg/m2 cyclophosphamide every three weeks, followed by four cycles of 100 mg/m2 docetaxel. They were randomly assigned to also receive concomitant 6 mg/kg trastuzumab every three weeks or 1,250 mg lapatinib per day throughout all cycles.

At baseline, patient characteristics were similar between the two groups, with both groups presenting a clinical median tumor size of 40 mm. The researchers also reported a similar number of patients in each group with T4a-c or T4d disease, bilateral, multifocal or multicentric disease, and estrogen receptor-negative and progesterone receptor-negative disease.

The last of the patients are currently undergoing surgery, and Untch will present histological and surgical outcome results for these patients at the symposium.

"After assessing response to neoadjuvant chemo-targeted therapy in patients with HER2 overexpressing tumors, we are following the patients from this study to see whether pathologic complete response at surgery is correlated to the outcome of the patients," he said.

### Follow the AACR on Twitter @AACR, and throughout the meeting using the hash tag #SABCS.

Recordings of the teleconferences and video interviews with researchers will posted to the AACR website throughout the meeting: http://www.aacr.org/page23506.aspx.

The mission of the CTRC-AACR San Antonio Breast Cancer Symposium is to produce a unique and comprehensive scientific meeting that encompasses the full spectrum of breast cancer research, facilitating the rapid translation of new knowledge into better care for breast cancer patients. The Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio, the American Association for Cancer Research (AACR) and Baylor College of Medicine are joint sponsors of the San Antonio Breast Cancer Symposium. This collaboration utilizes the clinical strengths of the CTRC and Baylor, and the AACR's scientific prestige in basic, translational and clinical cancer research to expedite the delivery of the latest scientific advances to the clinic. The 33rd annual symposium is expected to draw nearly 9,000 participants from more than 90 countries.



ELSE PRESS RELEASES FROM THIS DATE:

Pertuzumab and trastuzumab combination improved efficacy for women with HER2-positive breast cancer

2010-12-11
SAN ANTONIO — The combination of pertuzumab and trastuzumab had superior antitumor activity in women with early HER2-positive breast cancer, according to Phase II study results of the NeoSphere neoadjuvant trial. Details of these study results were presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12. "The findings establish that the addition of pertuzumab to trastuzumab and the chemotherapy drug docetaxel has an impressive rate of tumor eradication (46 percent), which is 50 percent more than achieved with docetaxel and trastuzumab, ...

Circulating tumor cells predicted recurrence, death in patients with early-stage breast cancer

2010-12-11
SAN ANTONIO — The presence of one to four circulating tumor cells (CTCs) in the blood of early-stage breast cancer patients almost doubled patient's risk of cancer relapse and death, and five or more CTCs increased recurrence by 400 percent and death by 300 percent, according to Phase III results of the SUCCESS trial. These cells were found in patients after surgery but before chemotherapy treatment. Results of this study were presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12, 2010, and demonstrate the value of CTCs in early breast ...

High CTC levels predicted poor outcome in metastatic breast cancer

2010-12-11
SAN ANTONIO — A high level of circulating tumor cells (CTCs) — cells that have detached from a tumor and are circulating in the body through the blood — are an independent prognostic marker in metastatic breast cancer as first-line therapy. In addition, persistence of high CTC level during therapy was found to be an early marker of poor outcome. "This is the largest, prospective series validating the prognostic value of CTCs in first-line chemotherapy metastatic breast cancer, independently from serum tumor markers for overall survival," said Jean-Yves Pierga, M.D., Ph.D., ...

Denosumab delayed time to first skeletal-related side effect

2010-12-11
SAN ANTONIO — For patients with breast cancer and bone metastases, denosumab delayed skeletal-related side effects five months longer compared to those on zoledronic acid, according to results presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12. "The average life expectancy of patients with metastatic breast cancer is approximately 2.5 years, so if you can prolong the time without a skeletal-related event by five months, you are substantially benefiting the patient," said Alison T. Stopeck, M.D., associate professor of medicine ...

CTCs predict poor outcome from blood stem cell transplantation therapy for metastatic breast cancer

2010-12-11
SAN ANTONIO — Metastatic breast cancer patients who had circulating tumor cells (CTCs) in their blood before or after high-dose chemotherapy (HDCT) followed by autologous stem cell transplantation had poor outcomes, according to researchers from the University of Texas MD Anderson Cancer Center. Patients with CTCs in their blood before chemotherapy treatment had reduced survival and those with these cells in their blood after the stem cell transplant recurred faster and died earlier. These findings were presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer ...

Phase III efficacy data on bevacizumab plus chemotherapy in early breast cancer to be presented

2010-12-11
SAN ANTONIO — Results of the GeparQuinto study, randomized Phase III efficacy data on the use of bevacizumab plus chemotherapy to treat women with early breast cancer will be presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium. Gunter von Minckwitz, M.D., Ph.D., managing director of the German Breast Group, and colleagues are conducting final analyses on efficacy data from this study, which will detail the early treatment of more than 1,900 patients with HER2-negative breast cancer treated with chemotherapy with or without bevacizumab. "So far, ...

FReD can help explain how a bee sees!

FReD can help explain how a bee sees!
2010-12-11
Bees can see colours but they perceive the world differently to us, including variations in hue that we cannot ourselves distinguish. Researchers at Queen Mary, University of London and Imperial College London have developed FReD – the Floral Reflectance Database – which holds data on what colours flowers appear to be, to bees. The development of the catalogue, which has involved a collaborative effort between researchers at two Schools at Queen Mary is reported in the journal PLoS ONE. The work addresses the existing issue that records of flower colours do not take ...

Boxing -- bad for the brain

2010-12-11
Up to 20% of professional boxers develop neuropsychiatric sequelae. But which acute complications and which late sequelae can boxers expect throughout the course of their career? These are the questions studied by Hans Förstl from the Technical University Munich and his co-authors in the current issue of Deutsches Ärzteblatt International (Dtsch Arztebl Int 2010; 107[47]: 835-9). Their evaluation of the biggest studies on the subject of boxers' health in the past 10 years yielded the following results: The most relevant acute consequence is the knock-out, which conforms ...

Wind and water have shaped Schiaparelli on Mars

Wind and water have shaped Schiaparelli on Mars
2010-12-11
The small crater embedded in the northwestern rim of the Schiaparelli impact basin features prominently in this new image from ESA's Mars Express. All around is evidence for past water and the great martian winds that periodically blow. Schiaparelli is a large impact basin about 460 km in diameter located in the eastern Terra Meridiani region of the equator of Mars. The centre of the basin lies at about 3°S/17°E and is named after the Italian astronomer Giovanni Schiaparelli (1835�). Although he also studied Mercury and Venus, he is best known for his observations ...

Beyond bars

2010-12-11
Despite threats of violence, imprisonment and death, writers around the world continue to fight to make their voices heard. The latest issue of Index on Censorship pays tribute to one of the world's longest running campaigns for free expression, English PEN's Writers in Prison Committee (WiPC). Founded in 1960, the WiPC supports and protects writers facing persecution around the globe. Contributors to Beyond Bars – including award-winning authors Margaret Atwood, Sir Tom Stoppard and William Boyd – highlight the vital role writers can play in supporting their colleagues. ...

LAST 30 PRESS RELEASES:

MSU team develops scalable climate solutions for agricultural carbon markets

Playing an instrument may protect against cognitive aging

UNM study finds link between Grand Canyon landslide and Meteor Crater impact

Ultra-hot Jupiter’s death spiral could reveal stellar secrets

You only get one brain! The best helmet material for protecting your noggin

Neurodegeneration and stroke after GLP-1RAs in diabetes and obesity

Pediatric COVID-19 hospitalization trends by race and ethnicity, 2020-2023

Research spotlight: New genetic roadmap offers insights into obesity and diabetes

Fred Hutch leads new Vanguard Study for Cancer Screening Research Network

‘Mismatched’ transplants now safe, effective for blood cancer patients, study finds

New research helps narrow down uncertainties in near-term precipitation projections for the Asian Water Tower

AI tool accurately detects tumor location on breast MRI

Researchers use OCT imaging to uncover how the fallopian tube transports embryos

PolyU secures RGC theme-based research scheme funding to develop cost-effective and sustainable Co-GenAI model

Van Andel Institute scientists develop technique for high-resolution single cell epigenetic analysis

The Lundquist Institute wins multi-year NIH grant exceeding $11 million to transform diagnosis and treatment of deadly mucormycosis

Review suggests ending adult boosters for tetanus, diphtheria

ESMT Berlin welcomes Rebecca Schaumberg to faculty

Blocking a little-known protein may offer new hope for devastating lung disease

Medieval medicine was smarter than you think – and weirdly similar to TikTok trends

FAU receives NIH grant to investigate amphetamine addiction

Realizing on-site carbon nanotube photo-thermoelectric imaging

Most of us love memes. But are they a form of comics?

Novel biosensor allows real-time monitoring of sucrose uptake in plants

Korea University researchers reveal revealing how WEE1 drives cancer resistance to immunotherapy

Pusan National University researchers develop breakthrough deep learning model that enhances handheld 3D medical imaging

SLAS Discovery and SLAS Technology demonstrate research impact with 2024 impact factors

Disease-causing bacteria can deal with stink as long as they get a meal

Mapping the metabolism of blood stem cells

UK air quality improved since 2015 but targets still missed

[Press-News.org] Phase III study compared neoadjuvant therapy with lapatinib or trastuzumab for early breast cancer